A Real-World Study of Patient Characteristics and Clinical Outcomes in <i>EGFR</i> Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice

A Real-World Study of Patient Characteristics and Clinical Outcomes in <i>EGFR</i> Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice

Osimertinib is a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR) that is used for first-line therapy in <i>EGFR</i> mutated non-small cell lung cancer (NSCLC) based on the results of the randomized FLAURA trial (ClinicalTrials.gov number NCT02296125). We performe...

Full description

Bibliographic Details
Main Authors: Hollis Viray, Andrew J. Piper-Vallillo, Page Widick, Emmeline Academia, Meghan Shea, Deepa Rangachari, Paul A. VanderLaan, Susumu S. Kobayashi, Daniel B. Costa
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Cancers
Subjects:
lung cancer
EGFR
osimertinib
real-world
time to treatment discontinuation
survival
Online Access:https://www.mdpi.com/2072-6694/16/6/1079

Internet

https://www.mdpi.com/2072-6694/16/6/1079

Similar Items